38th week of 2014 patent applcation highlights part 123 |
Patent application number | Title | Published |
20140271469 | CYSTINE KNOT PEPTIDES THAT BIND ALPHA-V-BETA-6 INTEGRIN - Disclosed are peptides comprising a molecular scaffold portion and a loop portion that binds to integrin α | 2014-09-18 |
20140271470 | TARGETED THERANOSTICS FOR METASTATIC PROSTATE CANCER - The present invention relates to methods of diagnosing and treating prostate cancer, including metastatic prostate cancer. Related pharmaceutical compositions are also provided. | 2014-09-18 |
20140271471 | THERMO-SENSITIVE BONE GROWTH COMPOSITIONS - A non-invasive injectable composition that contains type I collagen, an osteogenic growth factor (OSF), such as a bone morphogenetic protein and a reverse thermo-sensitive biodegradable polymer such as Poloxamer 407 in an aqueous vehicle. The formulation can be administered non-invasively, e.g., by injection, thus circumventing limitations of many currently marketed bone-inducing products. The injectable osteogenic formulation effectively induces bone formation at the desired locale. This injectable suspension could be used with bioresorbable bone mineral composites (e.g., Hydroxyapatite, Tri-calcium phosphate) and/or glycosaminoglycans (e.g., Hyaluronic acid, Heparin sulfate) to mold as putty and/slab as bone graft substitute implants to induce new bone formation in fracture healing and spine fusion procedures. | 2014-09-18 |
20140271472 | METHODS AND DEVICES FOR LUNG VOLUME REDUCTION WITH EXTRACELLULAR MATRIX MATERIAL - Lung volume reduction by isolating a target lung portion from the rest of the lung with a mass of extracellular matrix (“ECM”) material. The procedure can be performed by locating a tube within the lumen of an airway to be obstructed and depositing an amount of flowable or other ECM in the open space until the lumen is occluded. Optionally, the procedure may be performed by delivering a plug substantially comprised of ECM material into the lumen of an airway to be obstructed. Further optionally, the ECM plug may include a one-way valve to allow air and mucous to escape from the isolated lung portion. | 2014-09-18 |
20140271473 | ENCAPSULATED METAL ION NANOCLUSTERS - A metal ion nanocluster having a formula of X(OH) | 2014-09-18 |
20140271474 | INHIBITOR PROBES FOR IMAGING SODIUM-GLUCOSE COTRANSPORTERS IN HEALTH AND DISEASE - Radiolabeled tracers for binding to sodium/glucose cotransporters (SGLTs), and their synthesis, are provided. The tracers are high-affinity inhibitors of SGLTs, glycosides labeled with radioactive halogens. Also provided are in vivo and in vitro techniques for using the tracers as analytical tools to study the biodistribution and regulation of SGLTs in health and disease, and to evaluate therapeutic interventions. The ability to monitor radiolabel tracer disposition in real time enables the design of new SGLT inhibitors with lower metabolism and higher efficiency. | 2014-09-18 |
20140271475 | CELLULOSE NANOPARTICLE BIODEGRADABLE PHOTOACOUSTIC CONTRAST AGENTS - Biodegradable cellulose photoacoustic probes are provided that are able to detect biological targets and generate a detectable photoacoustic signal. The cellulose nanoparticles are biodegradable by cellulases. Clearance of the nanoparticles from a subject is enhanced and results in improved contrast of a photoacoustic-generated image. Methods to generate images by administering a cellulose nanoparticle probes to a subject and irradiating with light of a wavelength to emit photoacoustic energy detectable by sensors external to the subject are also provided. The detectable signal is convertible to a visual image of the nanoparticle probes in the subject. The methods may include allowing a cellulase to degrade nanoparticles so that undesirable background signals emitted are substantially reduced to increase the contrast and quality of the generated image. In the absence of an endogenous source of an enzyme for degrading the cellulose nanoparticles, a composition comprising a heterologous cellulase may be administered along with the nanoparticles. | 2014-09-18 |
20140271476 | SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS - The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds. | 2014-09-18 |
20140271477 | MONOCLONAL ANTIBODIES TO EGFR, AND USES THEREFOR - The present invention relates to isolated monoclonal anti-EGFR antibodies, and to the use of such antibodies and antibody fragments to detect EGFR, particularly those expressed by cancer cells. The antibodies are useful in diagnostic as well as therapeutic indications. Methods, devices and kits for the immunodetection and immunotherapy of cells expressing EGFR is also encompassed. | 2014-09-18 |
20140271478 | ANTIBODIES THAT BIND INTEGRIN ALPHA-V BETA-8 - Provided herein are antibodies with high affinity for the β8 subunit of αβ8. | 2014-09-18 |
20140271479 | OPTOGENETIC CONTROL OF INPUTS TO THE VENTRAL TEGMENTAL AREA - The present disclosure provides a method of inducing or modulating reward- or aversive-related behaviors in animals using light-responsive opsins. The present disclosure provides methods of identifying or screening compounds that may be used to treating mental disorders, or are relevant to disrupt or improve reward- or aversive related behaviors. | 2014-09-18 |
20140271480 | USES OF INDOLE-KETONES OR INDOLIDONES AS NEURO-PROTECTIVE DRUGS - The present invention provides a method of using indole-ketone or indolidone to treat or prevent a neurodegenerative disease or disorder. In one embodiment, the neurodegenerative disease is Parkinson's disease. In another embodiment, the neurodegenerative disease or disorder is associated with excessive neuronal Nitric Oxide Synthase (nNOS) activity. Examples of indole-ketone include, but are not limited to, SU4312, SU5416, SU11248 (Sunitinib), and indirubin-3-oxime. | 2014-09-18 |
20140271481 | MATRIX-INCORPORATED FLUORESCENT POROUS AND NON-POROUS SILICA PARTICLES FOR MEDICAL IMAGING - A silica particle for medical imaging includes a bridged silane fluorescent dye incorporated throughout the particle matrix. Copolymerization of a bridged silane fluorescent dye (e.g., (R′O) | 2014-09-18 |
20140271482 | SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS - The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds. | 2014-09-18 |
20140271483 | TARGETED POLYMERIC CONJUGATES AND USES THEREOF - Polymeric conjugates comprising a polymeric backbone having attached thereto a bone targeting moiety and a therapeutically active agent, wherein the bone targeting moiety is attached to one end of the polymeric backbone via a branching unit such that a molar ratio of the bone targeting moiety to the polymer is at least 2:1, are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of bone related disorders are also disclosed. | 2014-09-18 |
20140271484 | Methods of Imaging Inflammatory Diseases by Ligands Conjugated to Fluorescent Compounds - The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods of imaging of inflammatory diseases using the compounds. | 2014-09-18 |
20140271485 | USE OF COELENTERAZINE FOR IMAGING INSULIN-GENERATING BETA-CELLS - There is a need for a broadly applicable, strain non-specific, bioluminescent imaging tool that will enable researchers to study a β-cell mass in the context of development, disease or transplantation. The disclosure, therefore, encompasses embodiments of a method of identifying a non-diabetic pancreatic β-cell, the method comprising the steps of: delivering to a pancreatic β-cell a composition comprising a coelenterazine; allowing the β-cell to generate a coelenterazine-dependent bioluminescent signal; and identifying the cell as a non-diabetic pancreatic β-cell by detecting the emitted coelenterazine-dependent bioluminescent signal. | 2014-09-18 |
20140271486 | Quantum Dots for Diagnostic Imaging - Methods for detecting disease in a patient are disclosed. The methods involve administering to the patient a quantum dot-analyte conjugate, which includes an analyte that binds to a marker for the disease in the patient's gastrointestinal tract. The analyte is conjugated to a quantum dot having a characteristic emission wavelength. Using an endoscopic modality, a physician can illuminate portions of the patient's gastrointestinal tract and detect the presence of the marker based on emission of the quantum dot. Also disclosed are methods of predicting a response to a treatment in a patient. | 2014-09-18 |
20140271487 | PRUSSIAN BLUE-INSPIRED CONSTRUCTS FOR MULTIMODAL IMAGING AND THERAPY - The invention describes a coordination polymer construct for multimodal imaging and therapy. The construct consists of a core particle made of a novel coordination polymer. The core is coated with a biocompatible coating that stabilizes the particles in a physiological environment. The biocompatible coating can contain attached targeting agents, imaging agents and therapeutic agents or combinations one or more of the targeting, imaging and therapeutic agents. When administered to a subject or a subject-derived specimen, the resulting coordination polymer core-shell construct enables multimodal imaging and therapy, which improves the diagnostic and treatment outcomes of the conditions or diseases where it is administered. The invention describes the novel material, base for the construct, methods for the preparation of the said construct and its use as a multimodal imaging and therapy agent. | 2014-09-18 |
20140271488 | Chiral compounds of varying conformational rigidity and methods of synthesis - Synthesis of compounds having varying degrees of conformational rigidity is obtained via a low cost, high yield and efficient synthetic reactions. The library of compounds is structurally diverse having at least one or more chiral centers and providing large numbers of compounds having building block diversity and substantial scaffold diversity. The compounds further provide a novel method for obtaining candidate therapeutic agents for prevention, treatment or diagnosis of diseases. | 2014-09-18 |
20140271489 | POLYMERIC DEPOTS FOR LOCALIZATION OF AGENT TO BIOLOGICAL SITES - Provided herein are polymeric particles and compounds and processes that can be used to prepare polymer-based particles and methods of using those particles to localize or concentrate a subsequently delivered agent to an in vivo site. | 2014-09-18 |
20140271490 | BACTERIA-TARGETED MAGNETIC RESONANCE CONTRAST AGENTS - The present invention relates to bacteria-targeted contrast agents for magnetic resonance imaging (MRI). In particular, the present invention relates to bacteria targeted MRI contrast agents that can be used to detect bacteria in vivo or in vitro. In certain embodiments, the contrast agents comprise a metal chelate conjugated to at least two Zn-dipicolylamine groups. | 2014-09-18 |
20140271491 | ADHESIVE MEDICAL PRODUCTS AND METHODS FOR TREATING GASTROINTESTINAL LESIONS - The present invention relates to a long-lasting medical product for protecting or treating a lesion in the gastrointestinal tract. The medical product includes a protective covering, wherein the medical product upon application at and about the site of the lesion adheres to the gastrointestinal tissue and is capable of remaining at and about the site of the lesion for a time sufficient to allow the lesion to heal or be treated. | 2014-09-18 |
20140271492 | Manufacturing Process for Effervescent Dosage Forms - Methods of manufacturing effervescent dosage forms. Methods of manufacturing an effervescent tablet using a dry, direct compression process are disclosed. The methods do not result in the sticking of the mixture to be tableted to the punches during production. | 2014-09-18 |
20140271493 | (Trimethoxyphenylamino) Pyrimidinyl Formulations - There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them. | 2014-09-18 |
20140271494 | Wax Foamable Vehicle And Pharmaceutical Compositions Thereof - Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided. | 2014-09-18 |
20140271495 | Topical Copper Ion Treatments and Methods of Treatment Using Topical Copper Ion Treatments in the Oral-Respiratory-Otic Areas of the Body - Copper ion treatments and methods of treatment are provided to treat various body conditions affecting the oral, respiratory and/or otic areas of the body. The copper ion treatments contain copper ions which bring about local and systemic therapeutic effects as a result of contacting anatomical tissue of the oral cavity, the nasal passages or ear canal. The copper ion treatments and methods involve copper ion-containing solutions, copper ion toothpaste and copper ion mouthwash. The copper ion-containing solutions can be delivered to the oral cavity by spraying or swabbing, can be delivered to the nostrils as spray, drops, or by swabbing, and can be delivered to the ear canal as spray, drops, or by swabbing. The copper ion toothpaste is used for brushing the teeth, and the copper ion mouthwash is used for rinsing the mouth. | 2014-09-18 |
20140271496 | DENTAL MATERIAL AND METHOD - A dental material composed of hydrophilic polycaprolactone formed by the process of exposing a hydrophobic caprolactone to ionizing irradiation from a radiation source selected from the group consisting of an Electron Acceleration (E beam), Gamma II, Cobolt, X-ray or a source of UV radiation to form a cross linked polycaprolactone composition consisting of two distinct phases one of which is soluble and the other non-soluble, and adjusting the duration of ionizing radiation and/or the intensity of the radiation to cause the concentration of the soluble phase to be above at least about 65% by weight of the cured polymeric composition whereby the hydrophobic caprolactone becomes hydrophilic. | 2014-09-18 |
20140271497 | TREATMENT FOR DRY MOUTH EMPLOYING ORAL SAFE OXYGENATORS - A treatment for xerostomia, employing a composition having the active ingredient of safe oral oxygenator and a seed oil is described. The safe oral oxygenator can include either carbamide peroxide or sodium perborate and the seed oil can be macadamia nut oil. The oral care composition may further include one or more additives, such as glycerin (or another humectant), saliva enzyme, proanthocyanidins (e.g., PYCNOGENOL), resveratrol, a sugar alcohol, vitamin B | 2014-09-18 |
20140271498 | SURFACE-TREATED CALCIUM PHOSPHATE PARTICLES SUITABLE FOR ORAL CARE AND DENTAL COMPOSITIONS - Calcium phosphate particles are described comprising a surface treatment wherein the surface treatment comprises at least one sugar alcohol. Also described are various oral care compositions comprising surface treated calcium phosphate particles and methods of surface treating calcium phosphate particles. | 2014-09-18 |
20140271499 | ARTICLE AND METHOD OF INITIATING BONE REGROWTH AND RESTORATION OF GUM RECESSION WITH LOCALIZED SUBGINGIVAL DELIVERY OF MEDICATIONS - A system and method of initiating alveolar bone regrowth about a tooth of a patient suffering from bone loss due to periodontal disease that includes topically administering to a periodontal pocket about the tooth of the patient a hydrogen peroxide solution and topically administering to the periodontal pocket about the tooth a medicament that can help manage/control osteogenic activity. | 2014-09-18 |
20140271500 | METHODS AND MATERIALS FOR PROVIDING TEETH WITH A WHITE APPEARANCE - This document provides methods and materials for providing teeth with a white appearance. For example, methods and materials are provided for contacting teeth with one or more fluorescence emitting polypeptides (e.g., a blue fluorescent protein (BFP)) and adhesive molecules (e.g., mussel adhesive polypeptides) to provide the teeth with a whiter appearance. | 2014-09-18 |
20140271501 | Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities - The present disclosure relates to methods and compositions administered to the lymphatic tissue of an animal to prevent or reduce the incidence of disease or disease symptoms caused by one or more disease causing entities. Tonsillar compositions can be administered to the lymphatic tissue in the oral/nasal region of the animal and can include avian antibodies from eggs of hens inoculated with one or more target disease causing entities. Treating the lymphatic tissue in the oral/nasal region with the compositions described herein can reduce or prevent the disease causing entities from adhering to the lymphatic tissue resulting in reduced infection rates. The present disclosure also relates to oral compositions that can be used to reduce or eliminate oral pathogens in animals. | 2014-09-18 |
20140271502 | MOUTH RINSES AND TOOTH SENSITIVITY TREATMENT COMPOSITIONS - The present invention relates to tooth sensitivity treatment compositions, including mouth rinses, comprising C | 2014-09-18 |
20140271503 | Topical With Static Photobiological Functionality - Compositions and methods thereof, for preventing or minimizing skin penetration and that promote surface-layer fixation of dermatological molecules in a human body are disclosed. The molecules of the present invention and compositions containing said molecules comprise a tissue-reactive part, an amphiphilic part, a light-functional part and optionally a detachment mechanism for releasing said tissue-reactive part from said light-functional part. The methods include ways of combining the tissue-reactive part, amphiphilic part, light-functional part and optionally synthesizing a detachment mechanism therein. The parts when combined form molecular structures possessing novel photobiological persistence and efficacy. | 2014-09-18 |
20140271504 | COMPOSITION AND METHOD OF PRODUCING PERSONAL CARE COMPOSITIONS WITH IMPROVED DEPOSITION PROPERTIES - The presently disclosed and/or claimed inventive concept(s) relates generally to the use of nonionic hydrophobically modified polysaccharides in personal care and household care compositions. More specifically, but not by way of limitation, the presently disclosed and/or claimed inventive concept(s) relates to the use of hydrophobically-modified cellulose ethers, such as hydrophobically-modified hydroxyethylcellulose (HMHEC) polymers in personal care and household care compositions. These compositions show pronounced syneresis in aqueous solutions or in the presence of surfactants, including nonionic surfactants and anionic surfactants such as lauryl sulfate (LS) and lauryl ether sulfate (LES). It is also contemplated that the surfactants used in the compositions be sulfate free and/or multi-tailed. | 2014-09-18 |
20140271505 | Methods for Improving Skin Appearance - This disclosure concerns method for improving the appearance of skin. The methods includes various steps such as applying a cleanser to an area of skin to cleanse said area of skin; applying an exfoliating treatment to said area of skin; applying a first treatment composition to said area of skin after exfoliating; massaging said first treatment composition on said area of skin until a temperature of said area of skin increases; and applying a second treatment composition to said area of skin. | 2014-09-18 |
20140271506 | Cosmetic Compositions and Methods For Inhibiting Melanin Synthesis - A cosmetic composition suitable for topical application, for example, is provided. In some examples, the cosmetic composition may include undecylenoyl phenylalanine, hexyldecanol, and bisabolol. A method of reducing the synthesis of melanin by using said cosmetic compositions is also disclosed herein. | 2014-09-18 |
20140271507 | Skin Compositions and Uses - The present invention provides a skin care composition for maintaining or improving the healthy appearance of the skin of an individual and/or rejuvenate the skin of an individual. A skin care composition comprises active ingredients, including, without limitation, growth factors, anti-oxidants, curcuminoids, oils and/or red rice extracts. Among the growth factors comprising biologically active ingredients of the skin care composition are insulin like growth factor (IGF), an epidermal growth factor protein (EGFP), an insulin-like growth factor (IGF), a transforming growth factor beta (TGFβ), and erythropoiesis stimulating agent (ESA). The invention further provides a skin care composition for topical use to maintain or improve the health of the skin of an individual and/or rejuvenate the skin of an individual. | 2014-09-18 |
20140271508 | COSMETIC COMPOSITIONS AND USES THEREOF - Disclosed is a composition and methods for its use to reduce the appearance of cellulite and improve skin texture comprising a combination of one or more of | 2014-09-18 |
20140271509 | Compositions for Skin Lightening and/or Brightening - This disclosure describes compositions for skin lightening, brightening, whitening, reducing the appearance of age spot and/or improving the appearance of skin. The composition may include two or more tryosinase inhibiting compounds and one or more extracts from at least one plant species to inhibit alpha-Melanoctye-stimulating hormone. Other embodied compositions include at least one peptide having tyrosinase inhibiting qualities; at least on hydroquinone derivative; and at least one extract from at least one plant species. | 2014-09-18 |
20140271510 | WHITENING COSMETIC - Provided is a cosmetic agent superior in a whitening effect (including prophylaxis and removal of pigmented spot) and having high safety. In addition, a superior melanin production suppressive agent is provided. | 2014-09-18 |
20140271511 | Method And Compositions For Improving Wear Of Color Cosmetics - A composition comprising at least one non-sensitizing pressure sensitive adhesive that is the polycondensate of a silanol endblocked polydimethylsiloxane and a silicate resin; at least one copolymer of vinyl pyrrolidone and a long chain alpha olefin; at least one montmorillonite mineral; and at least one volatile solvent; and a related methods and kits. | 2014-09-18 |
20140271512 | COMBINATION DERMATOLOGICAL COMPOSITION AND USE - Compositions and methods for enhancing the aesthetic appearance of the skin of an animal, including the visible reduction of lines, creases, or wrinkles of the face, are achieved by applying to the surface of the skin a mixture of an aqueous composition containing urea, lactic acid, calcium pantothenate, and a lipophilic composition containing a lipid such as ceramide, lecithin, or a glycolipid. Optionally, glycerin can be included in the compositions. | 2014-09-18 |
20140271513 | FOOT ODOR REDUCTION COMPOSITION AND SYSTEM AND METHOD OF USE OF SAME - A foot odor reduction composition comprises ethanol, Vitamin B5, Vitamin E, and an effective amount of a mixture comprising an emulsifier, an antiseptic, and an ion holder for the application of foot odor. | 2014-09-18 |
20140271514 | Antiperspirant Compositions - A solid stick antiperspirant composition is provided. The antiperspirant composition includes aluminum zirconium tetrachlorohydrex glycine having a concentration from about 10% to about 35% by weight of the composition, an anhydrous liquid carrier, one or more structurants having a concentration from about 15% to about 25% by weight of the composition, wherein the one or more structurants comprises one or more waxes and a non-ionic exthoxylated linear alcohol having a carbon chain length from about 20 to about 40. The solid stick antiperspirant composition is a single phase. | 2014-09-18 |
20140271515 | Solid Stick Antiperspirant Compositions - A method of manufacturing a packaged solid stick antiperspirant composition is provided. The method includes combining an antiperspirant active, one or more structurants and a surfactant to form a mixture, dispensing the mixture from a nozzle to fill a dispensing package, forming a solid stick antiperspirant composition within the dispensing package. The surfactant has a melt temperature that is greater than the crystallization onset temperature of the solid stick antiperspirant composition. The antiperspirant active and the surfactant are in contact for about 5 minutes or less from the moment that the antiperspirant active and the surfactant and the structurant are mixed until the moment that the mixture is dispensed from the nozzle. | 2014-09-18 |
20140271516 | Methods of Making Solid Stick Antiperspirant Compositions - A method of manufacturing a packaged solid stick antiperspirant composition is provided. The method includes combining an antiperspirant active, one or more structurants and a surfactant to form a mixture, dispensing the mixture from a nozzle to fill a dispensing package, forming a solid stick antiperspirant composition within the dispensing package. The surfactant has a melt temperature that is greater than the crystallization onset temperature of the solid stick antiperspirant composition. The antiperspirant active and the surfactant are in contact for about 5 minutes or less from the moment that the antiperspirant active and the surfactant and the structurant are mixed until the moment that the mixture is dispensed from the nozzle. | 2014-09-18 |
20140271517 | DEODORANT FORMULATION - Deodorant formulations are provided. The formulations all commonly include magnesium oxide, zinc oxide and as a disinfecting agent, potassium chloride and/or potassium sulphate. The combination provides long lasting odour protection since the disinfectant destroys odour causing microorganisms. The formulations all contain natural ingredients and the absence of petroleum based or related synthetic compounds contributes to the efficacy of the formulations. | 2014-09-18 |
20140271518 | COSMETIC AEROSOL SPRAY WITH LASTING FRESHNESS EFFECT - A water-in-oil emulsion including a) at least one sweat-inhibiting aluminum salt, b) at least one water-in-oil emulsifier having an HLB value in the range from 1.5 to 6.5, c) at least one oil-in-water emulsifier or solubilizer having an HLB value in the range from >7 to 20, preferably in the range from >12 to 19, particularly preferably in the range from >14 to 18 and exceptionally preferably in the range from 15 to 17, d) at least one cosmetic oil that is not a fragrance and not an essential oil, e) 5-methyl-2-(1-methylethyl)cyclohexyl-N-ethyl oxamate, preferably (1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl-N-ethyl oxamate, at least one propellant, and an aerosol dispensing device have high emulsion stability due to a low corrosive tendency, a good cosmetic effect, a lasting freshness effect on the skin, good skin compatibility and low residue formation during and after application. | 2014-09-18 |
20140271519 | Specific Unsaturated and Branched Functional Materials For Use In Consumer Products - Novel poly-branched, mono- or poly-unsaturated functional materials are provided. More specifically, certain novel unsaturated branched functional compositions are provided that are made via isoprenoids and/or isoprenoid derivatives which come from either natural or synthetic sources. Also disclosed is their use or modification for use in consumer products such as laundry products, personal care products, dishcare products, shampoo products and hard surface cleaning products, and the like comprising the functional compositions or modified compositions. | 2014-09-18 |
20140271520 | NON-WEIGHING HAIR PREPARATIONS - An agent for treating keratin-comprising fibers, in particular human hair, which includes in a cosmetic carrier at least one cyclic siloxane, at least one C8 to C30 alkyl PEG/PPG dimethicone, and at least one cationic protein hydrolysate. | 2014-09-18 |
20140271521 | Process of Forming a Personal Care Article - A process for forming a personal care article, the process including (a) producing an extrudate from a twin screw extruder, and (b) forming the extrudate into the personal care article. The personal care article includes (i) from about 10% to about 60% of one or more anionic surfactants, wherein the one or more anionic surfactants have a Krafft point of less than 30° C.; (ii) from about 10% to about 50% of one or more water soluble polymers; (iii) from about 1% to about 30% of one or more plasticizers; and (iv) from about 10% to about 50% water. | 2014-09-18 |
20140271522 | DEODORANT COMPOSITION - It is intended to provide a novel deodorant composition which is excellent in the deodorizing effect, is capable of affording a deodorant composition by a convenient method, and shows no decrease in the deodorizing performance even after a long period of time, once the deodorant being prepared. Specifically, there is provided a deodorant composition containing, as the active component, a colored compound obtainable by reacting a polyphenol in a solvent showing alkalinity in the coexistence of an oxygen molecule at a reaction pH value of 6.5 or more. As a substitute for a polyphenol, use can be made of a plant extract containing a polyphenol but containing substantially no amino acid. It is also possible to further employ an amino acid. Furthermore, use can be made of a plant extract and/or a plant body containing a polyphenol and an amino acid. | 2014-09-18 |
20140271523 | Nitric Oxide Releasing Multifunctional Polymers - A molecule for stabilizing a bioactive chemical group capable of releasing nitric oxide in vivo is described. The molecule possesses multi-functionality, enabling the delivery of multiple nitric oxide precursors on a single molecule. In some embodiments, a tissue or prosthetic bonding group is attached to one of the functional arms of the molecule making the molecule of the present invention localizing to tissue or an implant. | 2014-09-18 |
20140271524 | Compositions for Improving Skin Appearance - Compositions for reducing the appearance of wrinkles, reducing the effects of aging and/or improving the appearance of skin. The composition may include at least one fluorinated perfluorocarbon; stem cells from at least one plant species; and at least one peptide complex that reduces release of acetylcholine. Other embodied compositions include at least one collagen stimulating peptide; at least one anti-inflammatory compound; and at least one skin tightening agent. | 2014-09-18 |
20140271525 | COSMETIC COMPOSITIONS - Disclosed is a composition and methods for its use capable of treating pruritus comprising a combination of one or more of an | 2014-09-18 |
20140271526 | ANTIMICROBIAL POLYAMIDE COMPOSITIONS AND MASTITIS TREATMENT - The present invention relates to veterinary compositions and methods of treating and/or preventing mastitis in non-human mammals. More particularly, the present invention relates to the treatment of mastitis in cows. The veterinary composition comprises a water soluble, locally-acting, antimicrobial amine functional polyamide polymer. | 2014-09-18 |
20140271527 | SUBCUTANEOUS DELIVERY OF POLYMER CONJUGATES OF THERAPEUTIC AGENTS - The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety. | 2014-09-18 |
20140271528 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION - Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease. | 2014-09-18 |
20140271529 | ANTIFUNGAL COMPOSITIONS FOR THE TREATMENT OF SECONDARY SKIN AND NAIL INFECTIONS - Disclosed herein are antifungal compositions and methods of using the same to treat secondary skin and nail infections. | 2014-09-18 |
20140271530 | CURCUMINOID COMPLEXES WITH ENHANCED STABILITY, SOLUBILITY AND/OR BIOAVAILABILITY - Methods and materials relating to a medicament preparation comprising a curcuminoid component and a eudragit component provided as a curcuminoid-eudragit complex, which enhance the bioavailability of the curcumin component and are useful for the treatment of various diseases including cancer, neurodegeneration, inflammation, and immunodeficiency. In some aspects, the curcuminoid component comprises curcumin to prepare a curcumin-eudragit complex and a medicament comprising curcumin-eudragit complexes. | 2014-09-18 |
20140271531 | In-Situ Forming Foam for Endoscopic Lung Volume Reduction - Systems and methods related to polymer foams are generally described. Some embodiments relate to compositions and methods for the preparation of polymer foams, and methods for using the polymer foams. The polymer foams can be applied to a lung at or near an alveolar duct targeted for reduction, occluding the airway and leading to tissue necrosis because the foam prevents oxygenation of the tissue surrounding the duct. In some embodiments, the polymer foams can be formed within a body cavity (i.e., in-situ foam formation). In addition, the foam may form a seal, eliminating the source of air leaks. | 2014-09-18 |
20140271532 | COMBINATION THERAPY WITH GLATIRAMER ACETATE AND RASAGILINE FOR THE TREATMENT OF MULTIPLE SCLEROSIS - The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject. | 2014-09-18 |
20140271533 | In-Situ Forming Foam for the Treatment of Vascular Dissections - Systems and methods related to polymer foams for the treatment of blood vessel dissections are generally described. Some embodiments relate to compositions and methods for the preparation of polymer foams, and methods for using the polymer foams. The polymer foams can be applied to or within a dissection caused by an intimal tear in a blood vessel, sealing the dissection and preventing further perfusion thereof. In some embodiments, the polymer foam can be formed within a body cavity (i.e., in-situ foam formation). The foam may be used to fill the dissection as a thrombosing agent. In addition, the foam may be used in conjunction with medical devices such as stents, stent-grafts, balloons, and catheters. | 2014-09-18 |
20140271534 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REPELLING AN INSECT FROM AN AREA, ARTICLE, AND/OR STRUCTURE - The disclosure provides for methods of repelling, directing, altering the behavior, and/or controlling an insect by utilizing a compound or composition described herein. The disclosure also provides for methods of repelling or directing an insect from an organism, article, or structure by utilizing a compound or composition described herein. The disclosure also provides for an article or structure treated with a composition including at least one repellent, controlling, or directing compound described herein. | 2014-09-18 |
20140271535 | COMPOSITIONS FOR ENHANCING POLLINATION AND METHODS FOR USING SAME - Aspects of the invention include compositions for enhancing pollination. Dry compositions according to certain embodiments include a carbon skeleton energy compound, macronutrients, a vitamin cofactor composition, micronutrients, an ionophore, and a source of extracted humate. Methods for using the dry compositions of the invention to enhance pollination are also described. | 2014-09-18 |
20140271536 | Bee Attractants - Chemical attractants to | 2014-09-18 |
20140271537 | DEUTERIUM-ENRICHED ALDEHYDES - The present invention generally relates to deuterium-enriched aldehydes, compositions comprising deuterium-enriched aldehydes, and methods for slowing the rate of aldehyde autoxidation. In one aspect, the present invention provides a composition comprising a compound of structure 1: | 2014-09-18 |
20140271538 | Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients - Disclosed are methods and compositions for treating, preventing and ameliorating conditions and diseases characterized by a lowered white blood cell count, including neutropenia, in human patients that are less than 18 years old. The methods and compositions described herein include a fusion polypeptide comprising human serum albumin protein (“HSA”) and human granulocyte-colony stimulating factor (“G-CSF”). | 2014-09-18 |
20140271539 | NOVEL USE OF MEMBERS OF IL-10 CYTOKINE FAMILY - The invention relates to a novel use of the members of the IL-10 cytokine family in wound healing. Particularly, the invention relates to the use of the member of the IL-10 cytokine family in the promotion of the proliferation and the migration of keratinocyte cells in wound healing. | 2014-09-18 |
20140271540 | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,- 3-d]pyrimidin-5(3H)-one, Salts thereof And Methods of Using The Same in Combination Therapy - This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): | 2014-09-18 |
20140271541 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS - Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease. | 2014-09-18 |
20140271542 | GENETIC MARKER FOR PREDICTING PROGNOSIS IN PATIENTS INFECTED WITH HEPATITIS C VIRUS - The present invention provides methods and materials for predicting the clinical outcome of a hepatitis C virus (HCV) infection. In particular, the invention relates to methods and materials for predicating the ability of an individual to spontaneously clear a hepatitis C virus infection. It also relates to methods and materials useful for predicting the clinical response of an individual suffering from HCV infection to administration of a therapeutic treatment. Also provided are kits for predicting the ability of an individual to spontaneously clear an HCV infection, or spontaneously clear such an infection. The methods and rated kits disclosed herein can also be used to develop a treatment plan for an individual infected with HCV, or who is at risk for developing such an infection. | 2014-09-18 |
20140271543 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS - New pyridin-2(1H)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK). | 2014-09-18 |
20140271544 | COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE SUB-POPULATION - The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in patients having genetic variations located near the IL28B gene, including SNP rs12979860 with a non-CC genotype and SNP rs8099917 with a non-TT genotype. | 2014-09-18 |
20140271545 | METHODS FOR PREDICTING RISK OF METASTASIS IN CUTANEOUS MELANOMA - The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set. | 2014-09-18 |
20140271546 | GENES AND GENE SIGNATURES FOR DIAGNOSIS AND TREATMENT OF MELANOMA - Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma. | 2014-09-18 |
20140271547 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV - Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-cyano, azido or amino nucleosides according to Formula 1001 or 2001: | 2014-09-18 |
20140271548 | DEVICE AND METHOD FOR PREPARING A FLUID COMPOSITION FOR COMPLETE OR SUPPLEMENTAL ENTERAL NUTRITION - The invention relates to a device for preparing a fluid composition for complete or supplemental enteral nutrition, comprising a liquid feeding device, an ingredient feeding device and a mixing device for mixing a liquid fed from the liquid feeding device and at least one ingredient fed from the ingredient feeding device, the mixing device comprising a mixer and a mixing container in which the liquid and the at least one ingredient are mixed by the mixer. The device is operable to move the mixing container relative to the mixer during mixing of the liquid and the at least one ingredient of the fluid composition to be prepared. Also provided is a method for preparing a fluid composition for complete or supplemental enteral nutrition using the device. | 2014-09-18 |
20140271549 | Use of Antibiotics to Enhance Treatment With Therapeutic Viruses - Provided are methods for increasing the therapeutic efficacy of viral therapy by administering an antibiotic effective against commensal bacteria with the viral therapy. Included are methods for treating cancers, tumors and metastases by administering the virus and the antibiotic. | 2014-09-18 |
20140271550 | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses - A CpG-modified recombinant adeno-associated viral (AAV) vector is described. The vector carries a nucleic acid molecule comprising AAV inverted terminal repeat (ITR) sequences and an exogenous gene sequence under the control of regulatory sequences which control expression of the gene product, in which the nucleic acid sequences carried by the vector are modified to significantly reduce CpG di-nucleotides such that an immune response to the vector is reduced as compared to the unmodified AAV vector. Also provided are methods and regimens for delivering transgenes using these AAV viral vectors, in which the innate immune response to the vector and/or transgene is significantly modulated. | 2014-09-18 |
20140271551 | Synthetic Adeno-Associated Virus Inverted Terminal Repeats - This invention relates to synthetic adeno-associated virus (AAV) inverted terminal repeats (ITRs) that exhibit altered activities compared to a naturally occurring AAV ITR and methods of using the same for delivery of nucleic acids to a cell or a subject. The synthetic ITRs provide a larger packaging capacity and the ability to manipulate activities such as transduction efficiency, cellular response to transduction, and transcription. | 2014-09-18 |
20140271552 | Nutritional Compositions Containing a Peptide Component and Uses Thereof - The present disclosure relates to nutritional compositions including a protein equivalent source including a peptide component comprising selected peptides from Tables 1 and 2 disclosed herein. The protein equivalent source may further include intact protein, hydrolyzed protein, including partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the incidence of autoimmune disease and/or diabetes mellitus by providing said nutritional compositions to a target subject, which includes a pediatric subject. | 2014-09-18 |
20140271553 | Nutritional Compositions Containing A Peptide Component with Anti-Inflammatory Properties and Uses Thereof - The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject. | 2014-09-18 |
20140271554 | Reducing Proinflammatory Response - The present disclosure provides a method for suppressing a proinflammatory response by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce the levels of proinflammatory cytokines and may be a treatment for inflammatory disease, especially type 1 diabetes. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da. | 2014-09-18 |
20140271555 | ACTIVATING ADIPONECTIN BY CASEIN HYDROLYSATE - The present disclosure provides a method for activating adiponectin by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce risk of heart attack and help in maintaining healthy weight. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da. | 2014-09-18 |
20140271556 | Magnetic Acoustic Resonance Light and Homeopathic Therapy Crystal - A quartz or otherwise similar crystal (‘host crystal’) embedded with minerals, metals, homeopathic, organic/inorganic, and magnetic materials (which allow for magnetic interactions) and the method for embedded ‘host crystal’ with said materials is disclosed. The ‘host crystal’ can be any size, shape, cut, or color of crystal. A hole/depression is first drilled/etched anywhere on the quartz or similar ‘host crystal’, this hole is then filled with a chosen combination of materials using force/compression, and are semi-permanently sealed by compressing metal flake or powder onto/into the top of the material-filled hole in the ‘host crystal’. The compression of the materials inside of the ‘host crystal’ increases the natural piezoelectric, ionic emission, magnetic field, and vibrational properties/emissions, allows for magnetic interactions, increases their scientific and potential therapeutic effects, and has applications for decorative specimens, energy healing/homeopathic/vibrational therapies, water energizing/structuring, and is most often incorporated into gem, mineral, magnetic, and homeopathic light therapies. | 2014-09-18 |
20140271557 | METHODS OF DIAGNOSING AND TREATING CANCER BY DETECTING AND MANIPULATING MICROBES IN TUMORS - In some embodiments, methods of determining that a subject is likely to have cancer are provided. Such methods may include amplifying a microbial DNA sample in a test sample obtained from the subject to determine an amount of microbial DNA in the test sample, wherein the amount of microbial DNA is determined by an amplification or sequencing technique; and determining that the subject is likely to have breast cancer when there is a significantly decreased level of microbial DNA in the test sample when compared to a level of microbial DNA in a control sample. In other embodiments, methods of treating cancer (e.g., breast cancer) are provided. In one aspect, such methods include administering a therapeutically effective dose of a probiotic organism via ductal lavage to a subject suffering from the breast cancer. | 2014-09-18 |
20140271558 | Dietary Supplements Including Glucan and Fulvic Acid - Beta glucan and fulvic acid can be combined in a dietary supplement as a partial substitute or complete replacement for blue green algae and/or brown seaweed and its derivatives. Beta glucans are widely available as derivatives of Brewer's yeast and fulvic acid is widely available as well. These supplements are not subject to the vagaries of weather-influence growing seasons as is the case with blue green algae and brown seaweed. When combined, beta glucan and fulvic acid can provide a less costly dietary supplement than blue green algae and brown seaweed and its derivatives such as fucoidan. | 2014-09-18 |
20140271559 | COMPOSITIONS AND METHODS FOR THE PRODUCTION AND DELIVERY OF DOUBLE STRANDED RNA - Compositions and methods for efficiently producing and delivering double stranded RNA (dsRNA) are provided. Vector constructs useful for in vitro and in vivo expression of dsRNA are described. Also described are cell expression systems for efficient and cost-effective production of dsRNA in living cells and methods and compositions for providing the expressed dsRNA to target organisms. The described compositions and methods can be used to produce RNA molecules for screening or other uses, and to amplify RNA sequences for analysis. | 2014-09-18 |
20140271560 | Methods for Using Cryptococcus Flavescens Strains for Biological Control of Fusarium Head Blight - Disclosed are methods of identifying subspecies of | 2014-09-18 |
20140271561 | METHODS OF DIAGNOSIS, SELECTION, AND TREATMENT OF DISEASES AND CONDITIONS CAUSED BY OR ASSOCIATED WITH METHANOGENS - The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof. | 2014-09-18 |
20140271562 | COMPOSITION FOR USE IN BRAIN GROWTH AND/OR COGNITIVE AND/OR PSYCHOMOTOR DEVELOPMENT - The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in brain growth and/or cognitive and/or psychomotor development. This composition is particularly adapted for use in infants, notably preterm infants. | 2014-09-18 |
20140271563 | EFFECT OF AN ATTENUATED BORDETELLA STRAIN AGAINST ALLERGIC DISEASE - Described herein are compositions, vaccines, and methods that include use of a mutated | 2014-09-18 |
20140271564 | VESICULAR STOMATITIS VIRUSES CONTAINING A MARABA VIRUS GLYCOPROTEIN POLYPEPTIDE - This document provides methods and materials related to vesicular stomatitis viruses containing a G polypeptide of a maraba virus. For example, vesicular stomatitis viruses containing a G polypeptide of a maraba virus (e.g., pseudotyped viruses), nucleic acid molecules encoding vesicular stomatitis viruses containing a G polypeptide of a maraba virus, methods for making vesicular stomatitis viruses containing a G polypeptide of a maraba virus, and methods for using vesicular stomatitis viruses containing a G polypeptide of a maraba virus to treat cancer or infectious diseases are provided. | 2014-09-18 |
20140271565 | FLUORAPATITE GLASS-CERAMICS - The present invention provides a highly-sintered fluorapatite glass-ceramic comprising a high Ca/Al or Sr/Al mole-ratio, that possesses a microstructure that induces apatite/bone deposition. | 2014-09-18 |
20140271566 | IN VITRO DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO PANCREATIC ENDODERM CELLS (PEC) AND ENDOCRINE CELLS - A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation. | 2014-09-18 |
20140271567 | METHODS OF TREATING OR PREVENTING RHEUMATIC DISEASE - The present disclosure provides a method for treating or preventing a rheumatic disease, comprising administering a population of cells enriched for STRO-1 | 2014-09-18 |
20140271568 | METHOD AND KIT FOR PROVIDING AN INCREASED EXPRESSION OF TELOMERASE, BRAIN-DERIVED NEUROTROPHIC FACTOR, STROMAL CELL-DERIVED FACTOR-1, CXC CHEMOKINE RECEPTOR 4, AND/OR IMMUNE REGULATORY FACTOR OF STEM CELL - A method for providing an increased expression of at least one of telomerase, brain-derived neurotrophic factor (BDNF), stromal cell-derived factor-1 (SDF1), CXC chemokine receptor 4 (CXCR4), and an immune regulatory factor of a stem cell in a subject is provided. The method comprises simultaneously or separately administering to the subject an effective amount of (a) a phthalide and (b) a stem cell. | 2014-09-18 |